FDA Approves Eton Pharma's KHINDIVI For Pediatric Adrenocortical Insufficiency

Eton Pharmaceuticals (ETON) received FDA approval for KHINDIVI (hydrocortisone) Oral Solution, a replacement therapy for pediatric patients with adrenocortical insufficiency, a rare condition affecting an estimated 5,000 U.S. patients aged 5-17. KHINDIVI, the only FDA-approved oral solution of hydrocortisone, offers a ready-to-use, accurately dosed alternative to tablets, and Eton anticipates peak sales exceeding $50 million annually when combined with ALKINDI SPRINKLE, with availability in the U.S. through Anovo specialty pharmacy.

Analysis

Eton Pharmaceuticals (ETON) has received U.S. Food and Drug Administration (FDA) approval for KHINDIVI Oral Solution, a hydrocortisone replacement therapy for pediatric patients aged five and older with adrenocortical insufficiency. This approval is significant as KHINDIVI is the sole FDA-approved oral solution formulation of hydrocortisone, offering a 1mg/ml strength designed for accurate dosing, thereby eliminating the need to split or crush tablets. The product is ready-to-use, requiring no refrigeration, mixing, or shaking, which simplifies administration for a patient population estimated by Eton to be over 5,000 individuals in the U.S. between 5 and 17 years old. Eton anticipates that peak annual sales for KHINDIVI, combined with its existing product ALKINDI SPRINKLE, will surpass $50 million. Distribution will be exclusively managed through Anovo, a specialty pharmacy, supported by the Eton Cares Program which provides services including prescription fulfillment, insurance investigation, and financial assistance, potentially offering $0 co-pays for eligible patients. It is important to note that KHINDIVI is not approved for increased dosing during stress periods, requiring an alternative hydrocortisone product for such events. This development directly impacts Eton's product portfolio and revenue potential within the rare disease market.

Key Decisions for Investors

• Investors should recognize the FDA approval of KHINDIVI as a material positive event for Eton Pharmaceuticals, potentially expanding its revenue base in the pediatric adrenocortical insufficiency market.
• Monitor the commercial launch, market uptake, and sales trajectory of KHINDIVI, particularly its contribution towards the stated peak sales target of over $50 million when combined with ALKINDI SPRINKLE.
• Assess the effectiveness of the exclusive distribution partnership with Anovo and the Eton Cares Program in driving patient adoption and compare actual market penetration against the estimated 5,000-patient U.S. pediatric market.